Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease

Ai Ling Lin, Jordan B. Jahrling, Wei Zhang, Nicholas Derosa, Vikas Bakshi, Peter Romero, Veronica Galvan Hart, Arlan Richardson

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Apolipoprotein E ϵ4 allele is a common susceptibility gene for late-onset Alzheimer's disease. Brain vascular and metabolic deficits can occur in cognitively normal apolipoprotein E ϵ4 carriers decades before the onset of Alzheimer's disease. The goal of this study was to determine whether early intervention using rapamycin could restore neurovascular and neurometabolic functions, and thus impede pathological progression of Alzheimer's disease-like symptoms in pre-symptomatic Apolipoprotein E ϵ4 transgenic mice. Using in vivo, multimodal neuroimaging, we found that apolipoprotein E ϵ4 mice treated with rapamycin had restored cerebral blood flow, blood-brain barrier integrity and glucose metabolism, compared to age-and gender-matched wild-type controls. The preserved vasculature and metabolism were associated with amelioration of incipient learning deficits. We also found that rapamycin restored the levels of the proinflammatory cyclophilin A in vasculature, which may contribute to the preservation of cerebrovascular function in the apolipoprotein E ϵ4 transgenics. Our results show that rapamycin improves functional outcomes in this mouse model and may have potential as an effective intervention to block progression of vascular, metabolic and early cognitive deficits in human Apolipoprotein E ϵ4 carriers. As rapamycin is FDA-approved and neuroimaging is readily used in humans, the results of the present study may provide the basis for future Alzheimer's disease intervention studies in human subjects.

Original languageEnglish (US)
Pages (from-to)217-226
Number of pages10
JournalJournal of Cerebral Blood Flow and Metabolism
Volume37
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Apolipoprotein E4
Asymptomatic Diseases
Sirolimus
Transgenic Mice
Blood Vessels
Alzheimer Disease
Learning
Neuroimaging
Cerebrovascular Circulation
Cyclophilin A
Blood-Brain Barrier
Alleles
Glucose
Brain
Genes

Keywords

  • Alzheimer's disease
  • APOE4
  • blood-brain barrier
  • Brain imaging
  • cerebral blood flow
  • cerebral glucose metabolism
  • cognition
  • inflammation
  • rapamycin

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease. / Lin, Ai Ling; Jahrling, Jordan B.; Zhang, Wei; Derosa, Nicholas; Bakshi, Vikas; Romero, Peter; Galvan Hart, Veronica; Richardson, Arlan.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 37, No. 1, 01.01.2017, p. 217-226.

Research output: Contribution to journalArticle

Lin, Ai Ling ; Jahrling, Jordan B. ; Zhang, Wei ; Derosa, Nicholas ; Bakshi, Vikas ; Romero, Peter ; Galvan Hart, Veronica ; Richardson, Arlan. / Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease. In: Journal of Cerebral Blood Flow and Metabolism. 2017 ; Vol. 37, No. 1. pp. 217-226.
@article{cbc7fcf8c4cd4084bfac3f8ac535b555,
title = "Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease",
abstract = "Apolipoprotein E ϵ4 allele is a common susceptibility gene for late-onset Alzheimer's disease. Brain vascular and metabolic deficits can occur in cognitively normal apolipoprotein E ϵ4 carriers decades before the onset of Alzheimer's disease. The goal of this study was to determine whether early intervention using rapamycin could restore neurovascular and neurometabolic functions, and thus impede pathological progression of Alzheimer's disease-like symptoms in pre-symptomatic Apolipoprotein E ϵ4 transgenic mice. Using in vivo, multimodal neuroimaging, we found that apolipoprotein E ϵ4 mice treated with rapamycin had restored cerebral blood flow, blood-brain barrier integrity and glucose metabolism, compared to age-and gender-matched wild-type controls. The preserved vasculature and metabolism were associated with amelioration of incipient learning deficits. We also found that rapamycin restored the levels of the proinflammatory cyclophilin A in vasculature, which may contribute to the preservation of cerebrovascular function in the apolipoprotein E ϵ4 transgenics. Our results show that rapamycin improves functional outcomes in this mouse model and may have potential as an effective intervention to block progression of vascular, metabolic and early cognitive deficits in human Apolipoprotein E ϵ4 carriers. As rapamycin is FDA-approved and neuroimaging is readily used in humans, the results of the present study may provide the basis for future Alzheimer's disease intervention studies in human subjects.",
keywords = "Alzheimer's disease, APOE4, blood-brain barrier, Brain imaging, cerebral blood flow, cerebral glucose metabolism, cognition, inflammation, rapamycin",
author = "Lin, {Ai Ling} and Jahrling, {Jordan B.} and Wei Zhang and Nicholas Derosa and Vikas Bakshi and Peter Romero and {Galvan Hart}, Veronica and Arlan Richardson",
year = "2017",
month = "1",
day = "1",
doi = "10.1177/0271678X15621575",
language = "English (US)",
volume = "37",
pages = "217--226",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease

AU - Lin, Ai Ling

AU - Jahrling, Jordan B.

AU - Zhang, Wei

AU - Derosa, Nicholas

AU - Bakshi, Vikas

AU - Romero, Peter

AU - Galvan Hart, Veronica

AU - Richardson, Arlan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Apolipoprotein E ϵ4 allele is a common susceptibility gene for late-onset Alzheimer's disease. Brain vascular and metabolic deficits can occur in cognitively normal apolipoprotein E ϵ4 carriers decades before the onset of Alzheimer's disease. The goal of this study was to determine whether early intervention using rapamycin could restore neurovascular and neurometabolic functions, and thus impede pathological progression of Alzheimer's disease-like symptoms in pre-symptomatic Apolipoprotein E ϵ4 transgenic mice. Using in vivo, multimodal neuroimaging, we found that apolipoprotein E ϵ4 mice treated with rapamycin had restored cerebral blood flow, blood-brain barrier integrity and glucose metabolism, compared to age-and gender-matched wild-type controls. The preserved vasculature and metabolism were associated with amelioration of incipient learning deficits. We also found that rapamycin restored the levels of the proinflammatory cyclophilin A in vasculature, which may contribute to the preservation of cerebrovascular function in the apolipoprotein E ϵ4 transgenics. Our results show that rapamycin improves functional outcomes in this mouse model and may have potential as an effective intervention to block progression of vascular, metabolic and early cognitive deficits in human Apolipoprotein E ϵ4 carriers. As rapamycin is FDA-approved and neuroimaging is readily used in humans, the results of the present study may provide the basis for future Alzheimer's disease intervention studies in human subjects.

AB - Apolipoprotein E ϵ4 allele is a common susceptibility gene for late-onset Alzheimer's disease. Brain vascular and metabolic deficits can occur in cognitively normal apolipoprotein E ϵ4 carriers decades before the onset of Alzheimer's disease. The goal of this study was to determine whether early intervention using rapamycin could restore neurovascular and neurometabolic functions, and thus impede pathological progression of Alzheimer's disease-like symptoms in pre-symptomatic Apolipoprotein E ϵ4 transgenic mice. Using in vivo, multimodal neuroimaging, we found that apolipoprotein E ϵ4 mice treated with rapamycin had restored cerebral blood flow, blood-brain barrier integrity and glucose metabolism, compared to age-and gender-matched wild-type controls. The preserved vasculature and metabolism were associated with amelioration of incipient learning deficits. We also found that rapamycin restored the levels of the proinflammatory cyclophilin A in vasculature, which may contribute to the preservation of cerebrovascular function in the apolipoprotein E ϵ4 transgenics. Our results show that rapamycin improves functional outcomes in this mouse model and may have potential as an effective intervention to block progression of vascular, metabolic and early cognitive deficits in human Apolipoprotein E ϵ4 carriers. As rapamycin is FDA-approved and neuroimaging is readily used in humans, the results of the present study may provide the basis for future Alzheimer's disease intervention studies in human subjects.

KW - Alzheimer's disease

KW - APOE4

KW - blood-brain barrier

KW - Brain imaging

KW - cerebral blood flow

KW - cerebral glucose metabolism

KW - cognition

KW - inflammation

KW - rapamycin

UR - http://www.scopus.com/inward/record.url?scp=85006512188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006512188&partnerID=8YFLogxK

U2 - 10.1177/0271678X15621575

DO - 10.1177/0271678X15621575

M3 - Article

C2 - 26721390

AN - SCOPUS:85006512188

VL - 37

SP - 217

EP - 226

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 1

ER -